A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, K. Gary Barnette, Robert H. Getzenberg, Domingo Rodriguez, Mitchell S. Steiner, Daniel R. Saltzstein, Mario A. Eisenberger, Emmanuel S. Antonarakis
Dive into the research topics of 'A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent'. Together they form a unique fingerprint.